Redhill Biopharma Ltd., of Tel Aviv, Israel, reported final results from a phase I study of Yeliva (ABC294640), an oral sphingosine kinase-2 selective inhibitor, in patients with advanced solid tumors, which met its primary and secondary endpoints, demonstrating that the drug is well-tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity.